Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juglans nigra pollen is a non-standardized allergenic extract derived from the pollen of the black walnut tree (Juglans nigra). It is used for both the diagnosis and treatment of allergies to black walnut pollen. [3, 4, 5, 7, 9, 11] For diagnosis, it is administered via percutaneous (skin prick) or intradermal tests to confirm hypersensitivity. [4] For treatment, it is used in allergen immunotherapy, administered as subcutaneous injections, to desensitize the patient's immune system to the allergen over time, thereby reducing allergic symptoms. [4, 5, 9, 11] This product is marketed by companies such as Greer Laboratories, Inc. (doing business as Stallergenes Greer). [8, 12] It is available as a single-allergen extract and is also included as a component in multi-allergen tree pollen mixes. [4, 15]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Juglans nigra pollen.